Technical Analysis for CTXR - Citius Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 1.13 1.80% 0.02
CTXR closed down 0.89 percent on Tuesday, January 15, 2019, on 1.74 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical CTXR trend table...

Date Alert Name Type % Chg
Jan 15 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.80%
Jan 15 Calm After Storm Range Contraction 1.80%
Jan 15 Narrow Range Bar Range Contraction 1.80%
Jan 15 NR7 Range Contraction 1.80%
Jan 15 Doji - Bullish? Reversal 1.80%
Jan 15 Oversold Stochastic Weakness 1.80%
Jan 14 New Uptrend Bullish 0.89%
Jan 14 Oversold Stochastic Weakness 0.89%
Jan 11 Calm After Storm Range Contraction -1.74%
Jan 11 Doji - Bullish? Reversal -1.74%

Older signals for CTXR ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30, 2016, the Company had not generate any revenues.
Is CTXR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 3 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.6
52 Week Low 0.936
Average Volume 104,319
200-Day Moving Average 1.9403
50-Day Moving Average 1.1953
20-Day Moving Average 1.087
10-Day Moving Average 1.14
Average True Range 0.1324
ADX 28.93
+DI 34.3747
-DI 8.8324
Chandelier Exit (Long, 3 ATRs ) 1.3928
Chandelier Exit (Short, 3 ATRs ) 1.3772
Upper Bollinger Band 1.209
Lower Bollinger Band 0.965
Percent B (%b) 0.59
BandWidth 22.447102
MACD Line -0.0121
MACD Signal Line -0.0263
MACD Histogram 0.0141
Fundamentals Value
Market Cap 9.16 Million
Num Shares 8.25 Million
EPS -1.98
Price-to-Earnings (P/E) Ratio -0.56
Price-to-Sales 0.00
Price-to-Book 1.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.17
Resistance 3 (R3) 1.17 1.16 1.16
Resistance 2 (R2) 1.16 1.14 1.16 1.16
Resistance 1 (R1) 1.13 1.13 1.13 1.13 1.15
Pivot Point 1.12 1.12 1.12 1.12 1.12
Support 1 (S1) 1.09 1.10 1.09 1.09 1.07
Support 2 (S2) 1.08 1.09 1.08 1.06
Support 3 (S3) 1.05 1.08 1.06
Support 4 (S4) 1.05